1. Name Of The Medicinal Product
Metopirone® Capsules 250mg
2. Qualitative And Quantitative Composition
Metyrapone BP 250mg.
3. Pharmaceutical Form
Yellowish-white, oblong, opaque, soft gelatin capsules printed 'CIBA' on one side and 'LN' on the other in brown ink.
4. Clinical Particulars
4.1 Therapeutic Indications
A diagnostic aid in the differential diagnosis of ACTH-dependent Cushing's syndrome. The management of patients with Cushing's syndrome.
In conjunction with glucocorticosteroids in the treatment of resistant oedema due to increased aldosterone secretion in patients suffering from cirrhosis, nephrosis and congestive heart failure.
4.2 Posology And Method Of Administration
Adults:
The capsules should be taken with milk or after a meal, to minimise nausea and vomiting, which can lead to impaired absorption.
For use as a diagnostic aid: the patient must be hospitalised. Urinary 17-oxygenic steroid excretion is measured over 24 hours on each of 4 consecutive days. The first 2 days serve as a control period. On the third day, 750mg Metopirone (3 capsules) must be given at four-hourly intervals to give a total of 6 doses (ie 4.5g). Maximum urine steroid excretion may occur on the fourth day. If urinary steroid excretion increases in response to Metopirone, this suggests the high levels of circulatory cortisol are due to adrenocortical hyperplasia following excessive ACTH production rather than a cortisol-producing adrenal tumour.
For therapeutic use: for the management of Cushing's syndrome, the dosage must be adjusted to meet the patient's requirements; a daily dosage from 250mg to 6g may be required to restore normal cortisol levels.
For the treatment of resistant oedema: The usual daily dose of 3g (12 capsules) should be given in divided doses in conjunction with a glucocorticoid.
Children: Children should be given a smaller amount based upon 6 four-hourly doses of 15mg/kg, with a minimum dose of 250mg every four hours.
Elderly: Clinical evidence would indicate that no special dosage regimen is necessary.
4.3 Contraindications
Primary adrenocorticol insufficiency. Hypersensitivity to Metopirone or to any of the excipients. Pregnancy.
4.4 Special Warnings And Precautions For Use
In relation to use as a diagnostic aid: anticonvulsants (eg phenytoin, barbiturates), anti-depressants and neuroleptics (eg amitriptyline, chlorpromazine), hormones that affect the hypothalamo-pituitary axis and anti-thyroid agents may influence the results of the Metopirone test. If these drugs cannot be withdrawn, the necessity of carrying out the Metopirone test should be reviewed.
If adrenocortical or anterior pituitary function is more severely compromised than indicated by the results of the test, Metopirone may trigger transient adrenocortical insufficiency. This can be rapidly corrected by giving appropriate doses of corticosteroids.
Long-term treatment with Metopirone can cause hypertension as the result of excessive secretion of desoxycorticosterone.
The ability of the adrenal cortex to respond to exogenous ACTH should be demonstrated before Metopirone is employed as a test, as Metopirone may induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity, as well as in patients with gross hypopituitarism.
Patients with liver cirrhosis often show a delayed response to Metopirone, due to liver damage delaying the metabolism of cortisol.
In cases of thyroid hypofunction, urinary steroid levels may rise very slowly, or not at all, in response to Metopirone.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
In some cases concomitant medication may affect the results of the Metopirone test (see Section 4.4, Special warnings and precautions for use).
4.6 Pregnancy And Lactation
No data are available from animal reproduction studies. Metopirone should not be administered during pregnancy since the drug can impair the biosynthesis of foetal-placental steroids. It is not known whether metyrapone passes into the breast milk, therefore nursing mothers should refrain from breast-feeding their infants during treatment with Metopirone.
4.7 Effects On Ability To Drive And Use Machines
Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness and sedation.
4.8 Undesirable Effects
Gastrointestinal tract: Occasional: nausea, vomiting. Rare: abdominal pain.
Central nervous system: Occasional: dizziness, sedation, headache.
Cardiovascular system: Occasional: hypotension.
Skin: Rare: allergic skin reactions.
Endocrine system: Rare: hypoadrenalism, hirsutism.
4.9 Overdose
Signs and symptoms: The clinical picture of acute Metopirone poisoning is characterised by gastrointestinal symptoms and acute adrenocortical insufficiency. Laboratory findings: hyponatraemia, hypochloraemia, hyperkalaemia. In patients under treatment with insulin or oral antidiabetics, the signs and symptoms of acute poisoning with Metopirone may be aggravated or modified.
Treatment: There is no specific antidote. Gastric lavage and forced emesis should be employed to reduce the absorption of the drug. In addition to general measures, a large dose of hydrocortisone should be administered at once, together with iv saline and glucose. This should be repeated as necessary in accordance with the patient's clinical condition. For a few days, blood pressure and fluid and electrolyte balance should be monitored.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Metopirone inhibits the enzyme responsible for the 11β-hydroxylation stage in the biosynthesis of cortisol and to a lesser extent, aldosterone. The fall in plasma concentration of circulating glucocorticoids stimulates ACTH secretion, via the feedback mechanism which accelerates steroid biosynthesis. As a result, 11-desoxycortisol, the precursor of cortisol, is released into the circulation, metabolised by the liver and excreted in the urine. Unlike cortisol, 11-desoxycortisol does not suppress ACTH secretion and its urinary metabolites may be measured.
These metabolites can easily be determined by measuring urinary 17-hydroxycorticosteroids (17-OHCS) or 17-ketogenic steroids (17-KGS). Metopirone is used as a diagnostic test on the basis of these properties, with plasma 11-desoxycortisol and urinary 17-OHCS measured as an index of pituitary ACTH responsiveness. Metopirone may also suppress biosynthesis of aldosterone, resulting in mild natriuresis.
5.2 Pharmacokinetic Properties
Metyrapone is rapidly absorbed and eliminated from the plasma. Peak plasma levels usually occur one hour after ingestion of Metopirone; after a dose of 750mg Metopirone, plasma drug levels average 3.7μg/ml. Plasma drug levels decrease to a mean value of 0.5μg/ml 4 hours after dosing. The half-life of elimination of Metopirone from the plasma is 20 to 26 minutes.
Metyrapol, the reduced form of metyrapone, is the main active metabolite. Eight hours after a single oral dose, the ratio of metyrapone to metyrapol in the plasma is 1:1.5. Metyrapol takes about twice as long as metyrapone to be eliminated in the plasma.
Seventy-two hours after a first daily dose of 4.5g Metopirone (750mg every 4 hours), 5.3% of the total dose was excreted in the urine as metyrapone (9.2% in free form and 90.8% conjugated with glucuronic acid), and 38.5% in the form of metyrapol (8.1% in free form and 91.9% conjugated with glucuronic acid).
5.3 Preclinical Safety Data
There are no pre-clinical data of relevance to the prescriber which are additional to those already included in other sections of the Summary of Product Characteristics.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Capsule contents: Glycerin, polyethylene glycol 400, polyethylene glycol 4000 and water. Capsule shell: Sodium ethylparaben, ethyl vanillin, gelatin, glycerin 85%, p-methoxy acetophenone, sodium propylparaben and titanium oxide (E171).
6.2 Incompatibilities
None stated.
6.3 Shelf Life
3 years
6.4 Special Precautions For Storage
Protect from moisture and heat. Store below 30°C.
6.5 Nature And Contents Of Container
High density polyethylene bottles of 100 capsules.
6.6 Special Precautions For Disposal And Other Handling
None stated.
Administrative Details
7. Marketing Authorisation Holder
Alliance Pharmaceuticals Ltd
Avonbridge House
Bath Road
Chippenham
Wiltshire
SN15 2BB
8. Marketing Authorisation Number(S)
PL16853/0010
9. Date Of First Authorisation/Renewal Of The Authorisation
June 1998
10. Date Of Revision Of The Text
30th June 2009
Legal status
POM
Alliance, Alliance Pharmaceuticals and associated devices are registered Trademarks of Alliance Pharmaceuticals Ltd.
No comments:
Post a Comment